|Day Low/High||0.00 / 0.00|
|52 Wk Low/High||0.00 / 0.00|
Mydayis demonstrated improvements lasting up to 16 hours post-dose, beginning at 2 or 4 hours post-administration, compared to placebo, in total score on a skill-adjusted math test that measures attention in ADHD
European stocks were mixed at the close of Wednesday's session ahead of a key date for both the U.K. and eurozone.
European stocks fell Tuesday as politics returned to forefront of investors' minds, with election talk in Italy and the U.K., and renewed transatlantic sabre rattling, all taking centre stage.
European stocks rebounded Friday as investors shook off the pessimism of recent days, with price action supported by both M&A as well as corporate earnings news.
Shire's success in phase 3 trials of Lanadelumab may mean it has also found a cure for a damaged track record in M&A.
Latest Research Supports Greater Understanding of the Evolving Needs of Adults with ADHD
Markets shrugged off weak industrial data from China to focus on economics and earnings news closer to home
Shire plc SHP shares shot to the top of the FTSE 100 Tuesday after the drugmaker beat expectations for earnings in the first-quarter and reiterated its full-year guidance.
Natpar is the first and only licensed recombinant human parathyroid hormone therapy for chronic hypoparathyroidism
Shire launches campaign to raise global awareness during World PI Week
PatientsLikeMe and Shire plc (LSE: SHP, NASDAQ: SHPG) have announced a new collaboration that will support the development of a patient-centered, real world health learning system that expands understanding of...
Benchmarks were higher on Tuesday following strong gains among commodity, consumer and airline stocks
Shire data presentations at AAAAI 2017 reinforce the efficacy, safety, and tolerability of CUVITRU for primary immunodeficiency patients